# Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor

> **NCT00095329** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 14 (actual)

## Conditions studied

- Multiple Sclerosis (MS) - Relapsing-remitting

## Interventions

- **BIOLOGICAL:** sirolimus

## Key facts

- **NCT ID:** NCT00095329
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-05
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Due to slow recruitment.
- **Last updated:** 2016-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095329, "Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00095329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*